Pfizer/BioNTech

Август 23, 2022

Содержание

2. 1 Pfizer BioNTech FDA Approval Letter Vaccine BNT162b - Comirnaty https://www.fda.gov/media/151710/download
3. 1 Pfizer BioNTech FDA Approval Letter Vaccine BNT162b - Comirnaty https://www.fda.gov/media/151710/download
4. 1 Pfizer BioNTech FDA Approval Letter Vaccine BNT162b - Comirnaty https://www.fda.gov/media/151710/download
5. 1 Pfizer BioNTech FDA Approval Letter Vaccine BNT162b - Comirnaty https://www.fda.gov/media/151710/download
6. 1 Pfizer BioNTech FDA Approval Letter Vaccine BNT162b - COMIRNATY https://www.fda.gov/media/151710/download
7. 1 Pfizer BioNTech FDA Approval Letter Vaccine BNT162b - COMIRNATY https://www.fda.gov/media/151710/download
8. 1 Pfizer BioNTech FDA Approval Letter Vaccine BNT162b - Comirnaty https://www.fda.gov/media/151710/download
9. July 7. 2020 – Moderna’s Patent for Current Vaccine Modified Polynucleotide or Production of Secreted Proteins
10. MODERNA US 10,703,789, B2. July 7, 2020 Articles 219, 220: LNP may be a gel, like
11. E MODERNA US 10,703,789, B2. July 7, 2020 MODERNA US 10,703,789, B2. July 7, 2020
12. https://www.nature.com/articles/s41428-020-0350-9
13. https://www.nature.com/articles/s41428-020-0350-9 HUNDREDS of Studies of Graphene-Oxide Incorporated Hydrogels
14. Pfizer/BioNTech vs Moderna Efficacy and “Breakthrough COVID-19” Cases MAYO Clinic – 5 States – 636,053 Subjects
15. 1 https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v1.full.pdf
16. 1 https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v1.full.pdf Inclusion Criteria for “COVID-19 Breakthrough Complications” Per Table 8. Definition Positive PCR test 3
18. Скачать презентацию

Слайд 2

1
Pfizer BioNTech FDA Approval Letter Vaccine BNT162b - Comirnaty
https://www.fda.gov/media/151710/download

Слайд 3

1
Pfizer BioNTech FDA Approval Letter Vaccine BNT162b - Comirnaty
https://www.fda.gov/media/151710/download

Слайд 4

1
Pfizer BioNTech FDA Approval Letter Vaccine BNT162b - Comirnaty
https://www.fda.gov/media/151710/download

Слайд 5

1
Pfizer BioNTech FDA Approval Letter Vaccine BNT162b - Comirnaty
https://www.fda.gov/media/151710/download

Слайд 6

1
Pfizer BioNTech FDA Approval Letter Vaccine BNT162b - COMIRNATY
https://www.fda.gov/media/151710/download

Слайд 7

1
Pfizer BioNTech FDA Approval Letter Vaccine BNT162b - COMIRNATY
https://www.fda.gov/media/151710/download

Слайд 8

1
Pfizer BioNTech FDA Approval Letter Vaccine BNT162b - Comirnaty
https://www.fda.gov/media/151710/download

Слайд 9

July 7. 2020 – Moderna’s Patent for Current Vaccine
Modified Polynucleotide or

Production of Secreted Proteins

Слайд 10

MODERNA US 10,703,789, B2. July 7, 2020
Articles 219, 220: LNP may

be a gel, like Hydrogel
Nanoparticles may form into a gel when injected into the subject
Polymer-based self-assembled nanoparticles…may be fully programmable

Слайд 11

E
MODERNA US 10,703,789, B2. July 7, 2020
MODERNA US 10,703,789, B2. July

7, 2020

Слайд 12

https://www.nature.com/articles/s41428-020-0350-9

Слайд 13

https://www.nature.com/articles/s41428-020-0350-9
HUNDREDS of Studies of
Graphene-Oxide Incorporated Hydrogels

Слайд 14

Pfizer/BioNTech vs Moderna Efficacy and “Breakthrough COVID-19” Cases
MAYO Clinic – 5

States – 636,053 Subjects – 18 and older
Dec 1, 2020 – July 19, 2021

Слайд 15

1
https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v1.full.pdf

Слайд 16

1
https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v1.full.pdf
Inclusion Criteria for “COVID-19 Breakthrough Complications”
Per Table 8. Definition
Positive PCR test

3 days before or up to 30 days after ‘COVID-19 Breakthrough Complications’
The number of Moderna subjects who experienced ‘COVID-19 Breakthrough Complications’
The number of Pfizer subjects who experienced ‘COVID-19 Breakthrough Complications’